Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 08, 2025.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals' board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations was ₹3,304.43 million (vs ₹3,172.75 million in Q1 FY25, up ~4% YoY), profit before tax rose to ₹595.06 million (vs ₹370.55 million), and profit after tax jumped to ₹448.67 million (vs ₹275.89 million, up ~63% YoY), translating to an EPS of ₹2.93. On a consolidated basis, revenue from operations was ₹10,240.32 million (vs ₹10,191.13 million in Q1 FY25, broadly flat), PBT was ₹956.46 million (vs ₹874.78 million), and PAT was ₹646.85 million (vs ₹612.08 million, up ~5.7% YoY) with EPS of ₹4.15. The statutory auditor's limited review report is clean (unqualified) but includes an emphasis-of-matter note regarding the Income Tax Department's search and seizure operations carried out in January 2025, whose outcome and financial impact remain unascertainable. The board also re-appointed Vibhor Gupta & Associates as internal auditor for FY 2025-26, re-constituted the Audit, Stakeholders Relationship, and Risk Management committees, and designated Rajkumar Bafna (President – Finance) and Tarun Kapoor (Sr. VP – IT) as Senior Management Personnel. The company confirmed that all ₹6,373.70 million of net IPO proceeds have been fully utilised as per the stated objects, with no deviation.
Strong standalone earnings growth (PAT up ~63% YoY) signals margin expansion and is broadly positive for shareholders, though consolidated growth was muted. The unresolved Income Tax search from January 2025 remains a key overhang – investors should monitor any future demand or order from the IT Department, as any adverse outcome could materially impact financials. Committee changes and internal auditor re-appointment are routine governance actions.